Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/15/2023* 09:00 EST Earnings Call Q4 2022 -- -- --
02/15/2023* -- Results Q4 2022 -- 2.77 --
10/26/2022 09:00 EST Earnings Call Q3 2022 -- -- --
10/26/2022 -- Results Q3 2022 2.48 2.38 4.00%
07/21/2022 -- Results Q2 2022 2.44 2.38 2.42%
07/21/2022 09:00 EST Earnings Call Q2 2022 -- -- --
04/27/2022 -- Results Q1 2022 2.47 2.42 2.24%
04/27/2022 09:00 EST Earnings Call Q1 2022 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 02/15/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 10/26/2022
Beat/Miss Upgrade
Return Since 9.13%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The Technology & Analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
URL https://www.iqvia.com
Investor Relations URL https://ir.iqvia.com
HQ State/Province North Carolina
Sector Healthcare
Industry Diagnostics & Research
Equity Style Large Cap/Blend
Next Earnings Release Feb. 15, 2023 (est.)
Last Earnings Release Oct. 26, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
16.63%
10.76%
28.73%
18.66%
33.00%
15.96%
57.47%
-21.83%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.17%
--
--
--
--
--
--
--
-78.00%
--
--
-69.32%
-82.16%
89.27%
213.6%
-67.34%
-75.83%
--
--
-68.13%
-86.04%
-6.70%
-52.96%
-4.45%
-64.33%
2.90%
-17.83%
-5.75%
-7.03%
17.26%
-5.15%
54.87%
0.78%
As of December 01, 2022.

Profile

Edit
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The Technology & Analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
URL https://www.iqvia.com
Investor Relations URL https://ir.iqvia.com
HQ State/Province North Carolina
Sector Healthcare
Industry Diagnostics & Research
Equity Style Large Cap/Blend
Next Earnings Release Feb. 15, 2023 (est.)
Last Earnings Release Oct. 26, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
IBB 317.55M USD 3.66%
PARMX 164.98M USD 2.62%
CCM1570 78.23M USD 2.15%
IGAF.TO 78.23M USD 2.15%
BBGLX 240.06M USD 1.51%
PGODX 94.36M USD 1.43%
VMGIX 266.66M USD 1.42%
VOT 266.66M USD 1.42%
IWP 140.22M USD 1.17%
VIMSX 913.49M USD 0.67%
VO 913.49M USD 0.67%
IWR 115.03M USD 0.41%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter IQV Tweets